Antiplatelet drugs femoropopliteal vein multicenter trial influence antiplatelet drugs patency femoropopliteal vein bypasses vascular surgeons patients double-blind trial aspirin mg dipyridamole mg placebo days surgery Graft occlusion independent coordinators cardiovascular events myocardial infarction stroke life table log rank confidence intervals CI Randomization comparable groups grafts rest pain gangrene Operative complications aspirin dipyridamole reoperations bleeding hematomas placebo NS graft failures early failure rates patient-months first months months subsequent years Cumulative graft patency placebo years aspirin plus dipyridamole difference patency CI year CI years significance mean follow-up months patient-years cardiovascular events myocardial infarction cerebrovascular accident patients placebo aspirin dipyridamole significant difference Antiplatelet therapy little influence femoropopliteal vein patency subsequent myocardial infarction stroke patients peripheral vascular disease 